Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026
Rhea-AI Summary
Edgewise Therapeutics (Nasdaq: EWTX) will present at the Leerink Global Healthcare Conference on March 11, 2026 at 1:40 p.m. ET. The company said the presentation will be webcast live and available for replay for a limited time.
Investors can find the webcast link on the Edgewise Events & Presentations page and are advised to connect several minutes early to ensure a timely connection.
Positive
- None.
Negative
- None.
News Market Reaction – EWTX
On the day this news was published, EWTX gained 0.24%, reflecting a mild positive market reaction. Argus tracked a peak move of +3.3% during that session. Argus tracked a trough of -7.7% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $7M to the company's valuation, bringing the market cap to $3.10B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum data flags mixed moves in peers, with AUPH up 3.04% and JANX down 1.79%, suggesting stock-specific factors rather than a unified biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 03 | Scientific conference | Neutral | -3.0% | Planned MDA data presentations on sevasemten and related Becker MD analyses. |
| Mar 02 | Inducement grants | Neutral | -2.4% | Inducement options for new employees under 2024 equity incentive plan. |
| Feb 26 | Earnings update | Neutral | -1.5% | Q4 and 2025 results with cash position and upcoming clinical catalysts. |
| Feb 05 | Investor conference | Neutral | -4.5% | Guggenheim biotech summit presentation with webcast access details. |
| Feb 02 | Inducement grants | Neutral | +2.6% | Stock option grants to new employees under Nasdaq inducement rules. |
Recent announcements, including conferences, inducement grants and earnings, have generally been followed by modest price moves without a clear directional pattern.
Over the past months, Edgewise reported Q4 and full-year 2025 results with $530.1M in cash and highlighted multiple late-stage programs, while also issuing routine inducement option grants and announcing several investor and scientific conference presentations. Despite these updates, 24-hour reactions around prior news skewed slightly negative. Today’s Leerink conference appearance fits the ongoing pattern of active investor and scientific outreach rather than a discrete pipeline or financial catalyst.
Market Pulse Summary
This announcement highlights Edgewise’s participation in the Leerink Global Healthcare Conference on March 11, 2026, continuing a series of recent investor and scientific engagements. It follows Q4 and full-year 2025 results that detailed a $530.1M cash position and multiple late-stage programs. Investors may watch for any incremental commentary on clinical timelines, cash runway, or strategic priorities, while also weighing recent regulatory filings and disclosed insider sales when assessing longer-term risk-reward.
AI-generated analysis. Not financial advice.
The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay for a limited time following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of symptomatic hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to edgewisetx.com or follow us on LinkedIn, X, Facebook and Instagram.
View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-present-at-the-leerink-global-healthcare-conference-on-march-11-2026-302699637.html
SOURCE Edgewise Therapeutics
FAQ
When will Edgewise Therapeutics (EWTX) present at the Leerink Global Healthcare Conference?
How can investors watch the Edgewise (EWTX) live webcast on March 11, 2026?
Will the Edgewise (EWTX) presentation at Leerink be available for replay after March 11, 2026?
What time should I connect to the Edgewise (EWTX) webcast on March 11, 2026 to avoid connection issues?
Where will Edgewise (EWTX) post the webcast link for the March 11, 2026 Leerink presentation?
